Skip to main content

Phase 3 Readout

VRDN: Phase 3 Topline: REVEAL-1 - A Phase 3, Randomized, Double-masked, Placebo-controlled, Efficacy, Safety, and Tolerabil

November 15, 2026 · vrdn-003. BioSniper AI can trace the company-impact path without requiring you to write the research question.

Event date
November 15, 2026
Company
Viridian Therapeutics, Inc.\DE (VRDN)
Drug
vrdn-003
BioSniper AIPage evidence connected

Prepared research question

What could this event change, and which evidence should be watched next?

Run cited research

Traceable citations · Unknowns marked

Phase 3 Readout~month

Phase 3 Topline: REVEAL-1 - A Phase 3, Randomized, Double-masked, Placebo-controlled, Efficacy, Safety, and Tolerabil

VRDN overview →
Drug
vrdn-003
Indication
Thyroid Eye Disease

Other upcoming events for VRDN

Phase 3 ReadoutPhase 3 Topline: A Randomized, Double-masked, Controlled, Safety and Tolerability Study of VRDN-003 in Participants W
Phase 3 ReadoutPhase 3 Topline: REVEAL-2 - A Phase 3, Randomized, Double-masked, Placebo-controlled, Efficacy, Safety, and Tolerabil